Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 12-week exercise program fight cancer-related muscle wasting?

NCT ID NCT06737692

Disease control Sponsor: Dokuz Eylul University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time

Summary

This trial tests whether a 12-week program of aerobic and resistance exercises can help people with gastrointestinal cancer and cachexia, a condition marked by severe weight and muscle loss. Researchers will compare an exercise group with a standard-care group, measuring changes in muscle strength, body composition, mobility, and quality of life. The goal is to see if exercise can ease the effects of cachexia and improve daily function during cancer treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A supervised and home-based program of aerobic and resistance exercises over 12 weeks
What this could lead to
If it works, this could point toward a way to help people with cancer-related wasting keep their strength, mobility, and quality of life during treatment.
What could go wrong
This is a small, early trial with 40 participants, so results may not apply to everyone. Exercise may be hard for people with cachexia, and the program's benefits are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Started

Nov 2025

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stage III-IV gastrointestinal cancer diagnosis * Age ≥ 18 years * Receiving systemic treatment (chemotherapy and/or targeted therapy and/or immunotherapy), at least 6 weeks after surgery, * Karnofsky performance score 80 and above, * Diagnosis of cachexia according to diagnostic criteria and Glasgow Prognostic Score (5,30) (\>5% weight loss in the last 6 months or \>2% weight loss in patients with BMI less than 20 kg/m2 or \>2% weight loss in sarcopenic individuals) Exclusion Criteria: * Musculoskeletal disorder * Neurological disorder * Severely impaired hematological capacity * History of cardiac disease * Uncontrolled hypertension * Severe renal insufficiency * Advanced osteoporosis * Decreased ability to stand or walk

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer cachexia (CC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia digestive system cancer Motor Activity neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer cachexia (CC)

Contacts and locations

Locations

  • Dokuz Eylül University

    Izmir, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.